Welcome to our dedicated page for Alto Neuroscience SEC filings (Ticker: ANRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alto Neuroscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alto Neuroscience's regulatory disclosures and financial reporting.
Alto Neuroscience, Inc. Schedule 13G/A amendment reports that Point72-related entities and Steven A. Cohen beneficially owned 1,170,865 shares of Common Stock, equal to 3.7% of the class as of the close of business on March 31, 2026.
The filing breaks holdings across affiliates: Point72 Asset Management and Point72 Capital Advisors report 503,087 shares (1.6%), and Point72 Biotech (with related entities) reports 667,778 shares (2.1%). Ownership is reported as shared voting and dispositive power; beneficial ownership is asserted through control relationships and advisory arrangements.
Alto Neuroscience ownership filing: Commodore Capital LP, Commodore Capital Master LP, and principals report beneficial ownership of 3,588,180 shares of common stock, reflecting direct holdings plus shares issuable upon exercise of a pre-funded warrant. The filing states an effective Beneficial Ownership Limitation of 9.99% and ties ownership percentages to 35,052,731 shares outstanding as of March 31, 2026. The report is a joint Schedule 13G/A filing by the investment manager and two managing partners and lists related voting and dispositive powers.
Alto Neuroscience, Inc. Schedule 13G reports that Sirenia Capital Management and Alex Silverstein together beneficially hold 2,591,587 shares of Common Stock, representing 7.9% of the class assuming exercise of certain warrants.
Securities outstanding were 31,945,516 shares as of March 16, 2026, per the referenced proxy statement. The position includes 787,043 shares issuable upon exercise of warrants, and the filing is made under Rule 13d-1(k) as a joint filing.
Alto Neuroscience director Ramiro Sanchez received a grant of stock options for 10,958 shares of common stock. The options have an exercise price of $24.63 per share and expire on May 11, 2036. All 10,958 underlying shares will vest on the earlier of the one-year anniversary of the grant date and the company’s next annual meeting, as long as he remains in continuous service. The options were issued under Alto Neuroscience’s Non-Employee Director Compensation Policy, and Sanchez paid no cash consideration for this award. Following this grant, he holds 10,958 derivative securities directly.
Alto Neuroscience, Inc. director Christopher Nixon Cox received a grant of stock options for 10,958 shares of common stock at an exercise price of $24.63 per share. These options vest on the earlier of one year from grant or the company’s next annual meeting, provided he continues in service, and were issued under the non-employee director compensation policy without any cash payment from him. Following this grant, he holds 10,958 stock options directly.
Alto Neuroscience director Manji Husseini received a stock option grant for 10,958 shares of common stock. The option has an exercise price of $24.63 per share and expires on May 11, 2036. The shares underlying the option vest on the earlier of the one-year anniversary of the grant date and the company’s next annual meeting, as long as he remains in continuous service. According to the disclosure, the option was issued under the non-employee director compensation policy and no cash consideration was paid for the grant. Following this award, Husseini holds options covering 10,958 shares directly.
Alto Neuroscience director Andrew Dreyfus received a grant of stock options covering 10,958 shares of common stock. The options have an exercise price of $24.63 per share and expire on May 11, 2036. They vest on the earlier of the one-year anniversary of the grant date or the company’s next annual meeting, as long as he continues in service through that date. According to the disclosure, he paid no cash consideration for this award, which was issued under the company’s Non-Employee Director Compensation Policy. Following this grant, he holds options for 10,958 shares directly.
Alto Neuroscience, Inc. director York Gwill received a grant of stock options covering 10,958 shares of common stock at an exercise price of $24.63 per share. The options were issued under the company’s Non-Employee Director Compensation Policy and required no cash payment by Gwill.
The options will vest on the earlier of the one-year anniversary of the grant date and the company’s next annual meeting, as long as Gwill continues to serve through that vesting date. After this grant, he holds options for 10,958 underlying shares directly.
Alto Neuroscience, Inc. reported results from its 2026 annual stockholder meeting. Of 31,945,516 common shares outstanding as of the record date, 26,762,809 shares, or about 83.77%, were represented, giving the company a strong quorum for voting.
Stockholders elected two Class II directors: Raymond Sanchez, M.D. received 23,133,161 votes for and 31,432 withheld, while Gwill York received 12,385,501 for and 10,779,092 withheld, with 3,598,216 broker non-votes for each. They ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 26,727,215 votes for. Stockholders did not approve an amendment and restatement of the 2024 Equity Incentive Plan related to treating pre-funded warrants like common shares for the plan’s evergreen share reserve, but did approve a similar amendment and restatement of the 2024 Employee Stock Purchase Plan.